Junshi Biosciences and Coherus Present Results of Phase 3 Study of Toripalimab in First Line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma at 2022 AACR Annual Meeting
– Toripalimab plus chemotherapy provided superior progression free survival, overall survival, overall response rate and duration of response compared to